Assessment of Suicidality in Epilepsy - Rating Tools (ASERT)
Sponsor: Eisai Inc.
A observational or N/A phase clinical study on Epilepsy, this trial is completed. The trial is conducted by Eisai Inc. and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
▶ Show 1 earlier version
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eisai Inc.
- GlaxoSmithKline
- H. Lundbeck A/S
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Pfizer
- Supernus Pharmaceuticals, Inc.
- The Epilepsy Study Consortium
- UCB Pharma
- Upsher-Smith Laboratories
For direct contact, visit the study record on ClinicalTrials.gov .